Scarce data exist on the relationship of C-reactive protein (CRP) or plasminogen activator inhibitor-1 (PAI-1) to the occurrence of heart failure (HF) or cardiogenic shock (CS) after acute myocardial infarction (AMI) and on the relationship between these biomarkers and mortality in CS patients. Thus, we compared high-sensitivity CRP and PAI-1 antigen plasma levels on admission among 3 age-and gender-matched AMI patients groups (consisting of 60 patients with CS, 60 with HF, and 60 without HF on admission), after determining that PAI-1 levels did not vary significantly diurnally in these groups by comparing the data among subgroups which were divided according to admission time within the groups. For CS patients, we also conducted regression analyses to examine the relations of these biomarkers to mortality. CRP levels both in CS (P < 0.001) and HF (P < 0.05) patients were significantly higher compared to those without HF, PAI-1 levels in CS patients were significantly higher compared to both those with (P < 0.05) and without HF (P < 0.01), and CRP and PAI-1 were independent predictors of in-hospital (Odds ratio [OR] = 6.12, 95% confidence intervals [95%CI] = 1.47-25.54 and OR = 5.92, 95%CI = 1.31-26.77, respectively) and 1-year mortality (OR = 5.53, 95%CI = 1.21-25.17 and OR = 5.48, 95%CI = 1.09-27.52, respectively) in CS patients. In conclusion, at admission, CRP is associated with the occurrence of CS and HF and PAI-1 is associated with the occurrence of CS after AMI, and they are of prognostic value in CS complicating AMI. (Int Heart J 2009; 50: 33-45) 
thrombo-inflammatory disorder. 1) It has been demonstrated in acute myocardial infarction (AMI) patients that admission levels of plasma C-reactive protein (CRP), which is a sensitive inflammatory marker, are elevated 2, 3) and associated with short-and long-term outcomes, [2] [3] [4] [5] including the occurrence of heart failure (HF) during the hospitalization period. 6) Moreover, inflammatory processes have also been suggested to play a role in the pathogenesis of cardiogenic shock (CS) complicating AMI. 7) Accordingly, there are studies reporting high CRP levels on admission among patients with CS complicating AMI. 8, 9) In these studies, it has also been shown that this measurement of CRP is associated with short-and long-term outcomes in CS patients. 8, 9) On the other hand, admission levels of plasminogen activator inhibitor-1 (PAI-1), which is a key regulator of the fibrinolytic system, have also been shown to be elevated [10] [11] [12] [13] and associated with adverse outcomes 10, 12, 14) in AMI patients. However, studies on the relationship between the admission PAI-1 levels and left ventricular (LV) functional status in AMI patients are scarce. 10, 15, 16) Of interest, it is well established that most of the therapeutic modalities that are currently used for AMI, ie, percutaneous coronary interventions (PCI), 17, 18) coronary artery bypass grafting (CABG), 19) and thrombolytics 12) have effects on CRP or/and PAI-1 levels. Accordingly, it seems to be appropriate to determine these biomarkers as far as possible before the start of these therapeutic interventions in such studies. On the other hand, it has been long demonstrated in healthy subjects and in patients with various diseases including ACS 20, 21) that PAI-1 has a diurnal rhythm, which could be also a confounding factor in any study evaluating this biomarker at admission (ie, at any time of the day). However, there are also studies reporting that the diurnal rhythm of PAI-1 is abolished in AMI patients. 11, 22) The aims of this study in patients in whom both plasma markers and LV functional status were determined on admission were to determine whether: (1) there is a significant alteration in diurnal rhythm of PAI-1 in AMI patients with different LV functional status, (2) there is an association between CRP and PAI-1 levels and the occurrence and severity of left ventricular dysfunction (LVD), (3) the values of these biomarkers would differ from the normative data in AMI patients without LVD, and (4) higher levels of these biomarkers are associated with in-hospital and 1-year mortality in AMI patients with CS.
Methods

Study design and patients:
This study was performed on 3 groups of AMI patients at Mersin University Hospital, Mersin, Turkey, between December 2001 and May 2008. The groups were established according to LV functional status on admission, and consisted of 60 consecutive patients with CS (CS group), 60 age-and gender-matched randomly selected patients with milder forms of LVD (HF group), and 60 age-and gender-matched randomly selected patients without LVD (no-LVD group). In these groups, plasma CRP and PAI-1 levels were determined within 6 hours of admission and before the initiation of PCI, CABG, thrombolytics or heparins, and the following analyses were made: (1) for determining possible alterations in the diurnal rhythm of PAI-1, the data were compared among the 4 subgroups which were divided according to admission time within each of the groups separately and in the total study sample; (2) CRP and PAI-1 levels were compared among the groups; and (3) within the CS group only, some clinical and laboratory variables were compared between the patients who survived and those who died during the hospital stay and 1-year follow-up and multivariable logistic regression analyses were conducted. Inclusion criteria: Only the patients who were admitted ≤ 12 hours from the symptom onset were included in the study, and the HF and CS groups included only patients in whom these complications were due to predominant LV failure, ie, patients with other causes of HF or CS (mechanical, valvular or therapeutic causes, isolated right ventricular failure, etc.) were excluded. Other exclusion criteria were previously known or newly diagnosed; significant hepatic or renal dysfunction or disease (persistent elevation of transaminases ≥ 3 times of the upper limit of normal, or serum creatinine > 2.5 mg/dL); haematological disorders (international normalized ratio > 1.2, activated partial thromboplastin time > 40 seconds, platelet count < 120 × 10 9 /L) or active haemorrhage); acute or chronic infectious or inflammatory diseases; and any other serious concomitant illnesses likely to alter prognosis; major trauma, surgery or PCI within the previous 2 months; any prior prosthetic material replacement; current use of anti-inflammatory (except low-dose aspirin), immunosuppressive, anticoagulant, or oestrogen and/or progestin containing drugs; receiving cardiopulmonary resuscitation before blood sampling; current fever (> 38°C), and pregnancy. Definitions: AMI was diagnosed in accordance with the European Society of Cardiology/American Heart Association Guideliness. 23) A cardiac troponin T value > 0.03 μg/L on at least one occasion within 24 hours after symptom onset with a rise or fall during subsequent sampling was considered to be positive. ST-segment elevation myocardial infarction (STEMI) was defined by elevation of the ST-segment > 0.1 mV in at least 2 contiguous leads or new onset of left bundle branch block. A diagnosis of CS was made if all of the following criteria were present: 24) (1) systolic blood pressure (BP) persistently (≥ 30 minutes) < 90 mmHg or vasopressors required to maintain a BP of > 90 mmHg; (2) signs of hypoperfusion (eg, urine output < 30 mL/h, cold/diaphoretic extremities, or an altered mental status), and (3) clinical evidence of elevated LV filling pressure (eg, pulmonary congestion on physical examination or chest X-ray). When available, CS criteria also included a cardiac index (CI) of < 2.2 L/minute/m 2 and a pulmonary capillary wedge pressure (PCWP) > 15 mmHg. HF was defined as the presence of rales and a third heart sound with gallop. A revascularization attempt (PCI or CABG) ≤ 12 hours after admission was defined as early invasive approach (EIA). Blood sampling and assays: The first 3-4 mL of blood was always discarded. Venous blood was drawn without stasis into both citrated and plain vacutainers, and immediately placed on melting ice and centrifuged within 60 minutes (2000 × g, 20 mintes at 4°C). Aliquots of plasma were snap-frozen immediately using solid CO 2 and stored at -80°C until determinations were performed (no longer than 3 months). High-sensitivity-CRP (hs-CRP) was measured in plasma with a latex-enhanced immunoturbidimetric assay (ADVIA Chemistry System, Bayer HealthCare AG, Leverkusen, Germany) on a Cobas Integra 800 System (Roche Diagnostics). Plasma PAI-1 antigen concentrations were measured by a doubleantibody technique with an ELISA kit (TintElize PAI-1, Trinity Biotech plc, Wicklow, Ireland) The reference ranges provided by the manufacturers were < 2.7 mg/L for CRP, and between 4 and 43 ng/mL for PAI-1. All assays were performed in duplicate and in a blinded fashion. Intra-assay coefficients of variation were 4.1 and 1.0 for PAI-1 and CRP, respectively.
All clinical decisions were made by the attending cardiologists. The study protocol was approved by the Institutional Ethics Committee. Written informed consent was obtained by either the patient or a surrogate. Statistics: First, the continuous variables were tested for normality (by the Kolmogorov-Smirnov test). Creatine kinase (CK), CRP, and PAI-1 concentrations were not normally distributed and underwent logarithmic transformation. The continuous variables were compared among the groups using 1-way analysis of variance (ANOVA) with post-hoc Bonferroni test where indicated and between the survival subgroups of CS group using the Mann-Whitney test. Categorical variables were analyzed using the χ 2 or Fisher's exact test. Kruskal-Wallis oneway ANOVA was used to compare PAI-1 among the admission-time subgroups within the groups and in the total sample. In logistic regression analyses, in-hospital and 1-year mortality were the dependent variables and age, gender, type of AMI (STEMI versus non-STEMI), the main management strategy (not receiving versus receiving an EIA), and CRP and PAI-1 levels were the independent variables. Data are expressed as the mean ± SD for parametric continuous variables, median (25th and 75th percentile) for nonparametric continuous variables, and numbers and percentages [n(%)] or n positive cases/n total cases assessed and % for categorical variables. All tests were 2-sided, and alpha was set at = 0.05. Analyses were performed with SPSS (version 13.0, SPSS, Inc., Chicago, USA) ACEI indicates angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CAG, coronary angiography; LMCA, left main coronary artery; and NA, not assessed. *Obtained by echocardiography at any time during the hospital stay, often while on support measures; † P < 0.001, P = NS, P < 0.001, and P < 0.001 for the whole model, for CS versus HF group, for CS versus no-LVD group, and for HF versus no-LVD group, respectively; ‡ P < 0.001, P = NS, P < 0.001, and P < 0.05 for the whole model, for CS versus HF group, for CS versus no-LVD group, and for HF versus no-LVD group, respectively; § P < 0.05 for the whole model, for CS versus HF group, for CS versus no-LVD group, and P = NS for HF versus no-LVD group. tended to be higher in association with the presence and severity of LVD. However, among them only the prevalence of multivessel disease (MVD) reached statistical significance (P < 0.05 for the whole model, for CS group versus HF group, for CS group versus no-LVD group, and P = NS for HF group versus no-LVD group). Among continuous variables, the mean time from the symptoms to blood sampling was statistically similar among the groups, whereas the mean left ventricular ejection fraction (LVEF) (P < 0.001, P = NS, P < 0.001, and P < 0.001 for the whole model, for CS group versus HF group, for CS group versus no-LVD group, and for HF group versus no-LVD group, respectively) and peak CK level (P < 0.001, P = NS, P < 0.001, and P < 0.05 for the whole model, for CS group versus HF group, for CS group versus no-LVD group, and for HF group versus no-LVD group, respectively) were significantly different. Alterations in the diurnal rhythm of PAI-1 (Table II) : None of the comparisons of PAI-1 levels among the admission-time subgroups within the study groups and for the total study sample revealed statistically significant differences. These findings led us to conclude that the diurnal rhythm of PAI-1 is abolished in our study samples. CRP and PAI-1 levels in groups (Table III) : In comparisons among the groups, ANOVA indicated significant differences both for CRP and PAI-1 levels (P < 0.001 and P < 0.01, respectively). In post-hoc analyses, CRP levels both in the 43 .0 *P < 0.001 for the whole model and for CS versus no-LVD group, P = NS for CS versus HF group, and P < 0.05 for HF versus no-LVD group; † P < 0.01, P < 0.05, P < 0.01, and P = NS for the whole model, for CS versus HF group, for CS versus no-LVD group, and for HF versus no-LVD group, respectively. 
CRP AND PAI-1 IN AMI WITH SHOCK AND HEART FAILURE
CS and HF groups were significantly higher than in the no-LVD group (P < 0.001, P < 0.05, respectively) and PAI-1 level in the CS group was significantly higher than in both the HF and no-LVD groups (P < 0.05 and P < 0.01, respectively). However, the difference in CRP and PAI-1 levels did not reach statistical significance between the CS and HF groups or between the HF and no-LVD groups. Additionally, it was also noted that the median values of both CRP and PAI-1 were higher than the upper limit of the reference range stated by the corresponding manufacturer (3.0 versus 2.7 mg/L for CRP and 54.5 versus 43.0 ng/mL for PAI-1). 
Effects of some demographic, clinical, and laboratory variables and CRP and
PAI-1 levels on mortality in CS patients: As shown in Table IV , the mean LVEF value was significantly lower (P < 0.05) and CRP (P = 0.01) and PAI-1 (P < 0.05) levels were significantly higher in CS patients who died during the hospital stay than in those who survived, whereas no significant differences were found for other variables. Additionally, very similar results were also obtained for comparisons on the basis of survival status at 1-year (data not shown). In the multivariable logistic regression analyses, elevated levels of both CRP and PAI-1 (tertile 3 versus tertiles 1 and 2 combined, for both) were independent predictors of both in-hospital and 1-year death, whereas age (> 70 versus ≤ 70 years), gender, type of AMI and EIA were not (Table V) .
Discussion
One of the findings of this study was the abolishment of the diurnal rhythm of PAI-1 in all AMI patient groups with different LV functional status and in the total study sample. This is consistent with two previous studies performed in general AMI patients. 11, 22) On the other hand, it has also been reported that the diurnal rhythm of PAI-1 is reversed in AMI patients. The authors have suggested that this reversal is due to the acute-phase reactant behaviour of PAI-1. 20) Accordingly, it is also possible that the abolishment of diurnal rhythm of PAI-1 observed in AMI patients is due to this property. In support of these assumptions, it has been demonstrated in an in vivo study that the decline in plasma PAI-1 antigen levels, owing to the diurnal changes, was counteracted by infusion of recombinant human tumour necrosis factor-α, 25) which is an inflammatory cytokine that plays an important role in AMI. 26) The main findings in this study are that, for the time of hospital admission, CRP level is elevated in association with the presence of both HF and CS and PAI-1 level is elevated in association with the presence of CS. Also among our findings were that both CRP and PAI-1 levels in AMI patients without LVD were higher than the upper limit of the corresponding manufacturer's reference range. Circulating CRP levels on admission have been shown to be elevated in AMI patients. 2, 3) The increase in CRP levels in these patients has been mainly explained by the stimulating effects of myocardial damage and necrosis on systemic inflammatory response. 27) However, there are also studies suggesting that elevated CRP levels in AMI patients may result from inflammation caused by the plaque rupture. 28) Moreover, it has also been suggested that CRP is not only a marker of inflammation, but also an active participant and amplifier in the process of AMI. 29) On the other hand, it has also been demonstrated that high CRP levels both on admission 6) and at peak 30) are associated with the occurrence of mild to severe HF (Killip class II to IV) during the hospitalization period in AMI patients, and there are also studies in which higher admission CRP levels were observed in AMI patients who developed CS during the pre-or postadmission period. 8, 9) In general, these observations are in agreement with our results. Nevertheless, to the best of our knowledge there are no studies examining the relationship between CRP levels and LVD when both of these factors were assessed on admission. Concerning the issue of the association between CRP and LVD after AMI, it has been demonstrated that the presence of a larger enzymatic infarct size and angiographically multiple complex lesions, both of which reflect the severity of the ongoing disease process, are associated with both the occurrence of HF and/ or CS [31] [32] [33] and increased levels of CRP 30, 33, 34) during the early phase of AMI. Of interest, several other factors related to a pre-existing medical condition, such as diabetes, hypertension, previous coronary heart disease (CHD), and MVD at angiography have also been shown to be associated with the occurrence of HF or CS after AMI, [35] [36] [37] but none of these factors are associated with increased CRP levels in this clinical setting. 4, 5, 30) Accordingly, it is logically possible that the link between CRP and LVD after AMI is due to the severity of the disease process, rather than a pre-existing medical condition. However, it has also been reported in some experimental studies of AMI 38) and in some clinical studies of patients with chronic HF 39) that LVD itself causes an increase in the plasma levels of some cytokines and CRP. Therefore, it is also possible that these mechanisms may play a role in the increase of CRP observed in AMI patients with LVD.
However, somewhat in contrast to the above observations, several studies have reported that there is no 4, 34) or an adverse 40) relationship between CRP levels on admission and LVEF and enzymatic measures of myocardial infarct size. The authors have explained these results by the time lag of 6 hours in the hepatic synthesis of CRP, 4) by the association of CRP elevation with preinfarction unstable angina pectoris accompanied by silent myocardial ischemia, which acts as ischemic preconditioning, and by the inductive effect of inflammation on expression of angiogenic growth factors associated with reduced infarct size and on endogenous production of nitrous oxide, which protects myocardium from reperfusion injury. 40) On the other hand, also consistent with our results, both basal levels of PAI-1 in the population-based studies 41, 42) and its acute-phase levels including those assessed on admission in the clinical studies [10] [11] [12] [13] have been shown to be elevated in AMI patients. However, the mechanisms behind this association is unclear. One possibility is that elevated PAI-1 is a primary risk factor for AMI, 42) and an alternative explanation is that metabolic, inflammatory or other factors associated with the development of AMI cause elevated PAI-1 levels. 41) In in vitro studies, cytokines increase PAI-1 production in both endothelial and HepG2 cells, 43, 44) but their role in vivo is unclear. However, there are only two studies, to our knowledge, that have examined the relationship between admission PAI-1 levels and LVD at shorter-term follow-up. In one of these studies, 10) although the PAI-1 antigen level was not correlated significantly with Killip class on admission and only slightly correlated with Killip class on discharge, a strong correlation between the admission PAI-1 activity level and Killip class both on admission and discharge was reported. In the other study, 15 ) the prevalence of a LVEF < 50% within one month was not significantly higher in AMI patients with an admission PAI-1 antigen level ≥ 43 ng/mL than in those with a lower level. It has also been reported in one study that the amount of acute release of PAI-1 is significantly higher in AMI patients in Killip class ≥ 3 on admission than in those with a less severe presentation. 16) Concerning this last issue, among the factors associated with the occurrence of LVD after AMI, the presence of diabetes 45, 46) and larger enzymatic infarct size 31, 32) have also been shown to be associated with increased levels of PAI-1 in this setting. 10, 13 ) Therefore, it is not possible to conclude that our finding of an association between higher PAI-1 levels and the occurrence of CS in AMI patients is merely due to a pre-existing medical condition or severity of the ongoing disease process. However, in a number of experimental studies, PAI-1 has been proposed to play an important role in ventricular remodelling after AMI. 47, 48) Finally, in this study higher levels of both CRP and PAI-1 on admission were independent predictors of in-hospital and 1-year mortality in CS patients. While elevated levels of circulating CRP on admission have been rather clearly demonstrated to be an independent predictive factor for adverse outcomes both for hospital stay and longer time periods in ACS patients or specifically in AMI patients, [3] [4] [5] [6] [7] this association has been reported only for the hospital stay 10, 12) and for 30-day follow-up 14) for PAI-1. However, to our knowledge, there are only two studies 8, 9) addressing the relationship between CRP levels on admission and clinical outcomes and no studies addressing this issue for PAI-1 in patients with CS complicating AMI. In these last studies, among AMI patients with pre-or postadmission CS who underwent primary PCI, CRP level was associated with in-hospital mortality and was an independent predictor of 1-year major adverse cardiac events. 8, 9) In conclusion, for the time point of hospital admission, CRP level is associated with the occurrence of both HF and CS and PAI-1 level is associated with the occurrence of CS after AMI, and both of these markers are independent predictors of in-hospital and 1-year mortality in CS complicating AMI.
With respect to the limitations of this study, it can be stated that (1) the lack of a control group consisting of healthy persons makes it impossible to properly compare CRP and PAI-1 values obtained in AMI patients without LVD with the normative data, (2) the relatively small number of patients in our study groups makes it impossible to examine the factors that may contribute to the elevated levels of CRP and PAI-1 observed in AMI patients with LVD, and (3) this later factor may also account for the lack of statistical significance for the relationships between the variables age and EIA and mortality rates, which is inconsistent with a number of previous studies with larger sample sizes. 24, 46) 
